Corpus 1,272 assessed · 1,173 scored · 643 reproduced ≥75 · 168 flagged ·∅ 74.1/100

Publications 2 Datasets 392.5k Experiments 4.7k

Explore

Filters: partial ✕ Peking University ✕ Medicine ✕ clear all

2 matching publication(s)

Publication	Journal	Year	Score	Verdict
Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant NSCLC: Phase 2 trial interim results (NEOTIDE/CTONG2104). PMID 38897205	Cell Rep Med	2024	72	L1 72/100
Improved precision of epigenetic clock estimates across tissues and its implication for biological ageing. PMID 31443728	Genome Med	2019	68	L1 68/100

Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant NSCLC: Phase 2 trial interim results (NEOTIDE/CTONG2104).

PMID 38897205 · Cell Rep Med · 2024

L1 72/100

Improved precision of epigenetic clock estimates across tissues and its implication for biological ageing.

PMID 31443728 · Genome Med · 2019

L1 68/100